Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma
Go back to Pfizer Receives FDA Approval for SUTENT® (sunitinib malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma| Pfizer Inc. (NYSE: PFE) | Delayed: 24.72 -0.36 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $25.08 | 52 Week High | $37.39 | |||
| Open | $24.99 | 52 Week Low | $28.25 | |||
| Day High | $25.24 | P/E | 14.98 | |||
| Day Low | $24.69 | EPS | $1.65 | |||
| Volume | 81,959,343 | |||||
